| Methods |
Inclusion criteria= SBP 160‐210 mm Hg and DBP 95‐115 mm Hg based on 3 separate measurements over a period of several days; approximately 8‐week (60 days) double‐blind treatment |
| Participants |
All patients: n=13(4 males,9 females);
Captopril 75 mg daily: n=8(3 males,5 females); mean age=63(9) years; baseline upright SBP=155.3(7.9) mm Hg, DBP=94.4(10.9) mm Hg; baseline lying SBP=164.3(10.4) mm Hg, DBP=96.5(10.7) mm Hg; baseline HR=64.5(10.7) bpm;
Placebo: n=5(1 male,4 females); mean age=63(4) years; baseline upright SBP=157.1(10.6) mm Hg, DBP=103.0(16.2) mm Hg; baseline lying SBP=168.1(7.0) mm Hg, DBP=100.4(11.1) mm Hg; baseline HR=66.2(4.9) bpm |
| Interventions |
Captopril 75 mg daily (50 mg in the morning, 25 mg at bedtime);
Placebo |
| Outcomes |
Upright SBP/DBP using Dynamap automated oscillometric device;
WDAE |
| Notes |
BP change and SD of change not reported; endpoint BP and SD reported; imputed endpoint SD for SD of change; BP data from Table III, p. 150; lying BP data also available; Jadad score=3; funding source= not reported |
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Allocation concealment? |
Unclear risk |
B ‐ Unclear |
